TapewireFind a company

person · Reporting owner

Wang Julia Aijun

Disclosed activity across 2 companies

Tapewire entity
66570
SEC CIK
0001860279

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
BeOne Medicines Ltd.BGNE · Entity 2168Chief Financial OfficerJuly 01, 2024July 03, 2024
LABCORP HOLDINGS INC.LH · Entity 1277Chief Financial Officer, EVPFebruary 11, 2026February 13, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BeOne Medicines Ltd.

Report date July 01, 2024 · Filed July 03, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
American Depositary SharesSEC Table I · non-derivativeDirect0 Reported balance After 2024-07-01 transaction · row 2 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 2 · 2024-07-01 · Sale · Disposed 472 · Balance 0

F1: Each American Depositary Share represents 13 Ordinary Shares.

F2: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 30, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.8513 to $144.06, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Ordinary SharesSEC Table I · non-derivativeDirect426,595 Reported balance Holding disclosure · report date 2024-07-01 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 426,595

Filing footnotes · ownership attribution and instrument terms

F1: Each American Depositary Share represents 13 Ordinary Shares.

F2: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 30, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.8513 to $144.06, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

LABCORP HOLDINGS INC.

Report date February 11, 2026 · Filed February 13, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect1,817.239 Ending reported balance After 2026-02-11 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-02-11 · Exercise / conversion · Acquired 860 · Balance 2,062.239

F1: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

Row 2 · 2026-02-11 · Tax withholding · Disposed 245 · Balance 1,817.239

F2: Stock withholding to satisfy tax withholding obligations.

Restricted Stock UnitSEC Table II · derivative / convertible securityDirect4,964 Reported balance After 2026-02-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-02-11 · Exercise / conversion · Disposed 860 · Balance 4,964

F1: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

F3: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2026.

F4: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

F2: Stock withholding to satisfy tax withholding obligations.

F3: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2026.

F4: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 11, 2026 Filed Feb 13, 2026 18:16 UTC LABCORP HOLDINGS INC. LH · Entity 1277 Exercise / conversionRestricted Stock Unit · Derivative 860 $0.00 $0.00
Disclosure

SEC source: 0000920148-26-000090 · form4.xml · derivative · entry 3

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,964

Underlying: Common Stock · 860 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2026.

F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2026.

F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

Read SEC document
February 11, 2026 Filed Feb 13, 2026 18:16 UTC LABCORP HOLDINGS INC. LH · Entity 1277 Tax withholdingCommon Stock 245 $289.89 $71,023.05
Disclosure

SEC source: 0000920148-26-000090 · form4.xml · nonDerivative · entry 2

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,817.239

F2 · kind: Stock withholding to satisfy tax withholding obligations.

Read SEC document
February 11, 2026 Filed Feb 13, 2026 18:16 UTC LABCORP HOLDINGS INC. LH · Entity 1277 Exercise / conversionCommon Stock 860 Not disclosed Not disclosed
Disclosure

SEC source: 0000920148-26-000090 · form4.xml · nonDerivative · entry 1

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,062.239

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

Read SEC document
February 10, 2026 Filed Feb 12, 2026 20:41 UTC LABCORP HOLDINGS INC. LH · Entity 1277 GrantRestricted Stock Unit · Derivative 2,350 $0.00 $0.00
Disclosure

SEC source: 0000920148-26-000066 · form4.xml · derivative · entry 2

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,824

Underlying: Common Stock · 2,350 shares

Expires not disclosed

F3 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

F4 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 10, 2027.

F4 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 10, 2027.

F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

Read SEC document
February 10, 2026 Filed Feb 12, 2026 20:41 UTC LABCORP HOLDINGS INC. LH · Entity 1277 GrantNon-qualified Stock Options · Derivative 7,100 $0.00 Strike: $284.50 $0.00
Disclosure

SEC source: 0000920148-26-000066 · form4.xml · derivative · entry 1

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,100

Underlying: Common Stock · 7,100 shares

Expires 2036-02-09

F1 · security: Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan.

F2 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column.

Read SEC document
February 06, 2026 Filed Feb 10, 2026 20:34 UTC LABCORP HOLDINGS INC. LH · Entity 1277 Exercise / conversionRestricted Stock Unit · Derivative 893 $0.00 $0.00
Disclosure

SEC source: 0000920148-26-000036 · form4.xml · derivative · entry 3

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,474

Underlying: Common Stock · 893 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 6, 2025.

F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 6, 2025.

F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

Read SEC document
February 06, 2026 Filed Feb 10, 2026 20:34 UTC LABCORP HOLDINGS INC. LH · Entity 1277 Tax withholdingCommon Stock 254 $277.20 $70,408.80
Disclosure

SEC source: 0000920148-26-000036 · form4.xml · nonDerivative · entry 2

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,202.239

F2 · kind: Stock withholding to satisfy tax withholding obligations.

Read SEC document
February 06, 2026 Filed Feb 10, 2026 20:34 UTC LABCORP HOLDINGS INC. LH · Entity 1277 Exercise / conversionCommon Stock 893 Not disclosed Not disclosed
Disclosure

SEC source: 0000920148-26-000036 · form4.xml · nonDerivative · entry 1

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,456.239

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

Read SEC document
February 11, 2025 Filed Feb 13, 2025 16:18 UTC LABCORP HOLDINGS INC. LH · Entity 1277 GrantRestricted Stock Unit · Derivative 2,580 $0.00 $0.00
Disclosure

SEC source: 0001127602-25-004529 · form4.xml · derivative · entry 2

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,367

Underlying: Common Stock · 2,580 shares

Expires not disclosed

F3 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

F4 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2026.

F4 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2026.

F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

Read SEC document
February 11, 2025 Filed Feb 13, 2025 16:18 UTC LABCORP HOLDINGS INC. LH · Entity 1277 GrantNon-qualified Stock Options · Derivative 7,800 $0.00 Strike: $245.14 $0.00
Disclosure

SEC source: 0001127602-25-004529 · form4.xml · derivative · entry 1

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,800

Underlying: Common Stock · 7,800 shares

Expires 2035-02-10

F1 · security: Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. Amended and Restated 2016 Omnibus Incentive Plan.

F2 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column.

Read SEC document
February 06, 2025 Filed Feb 10, 2025 14:00 UTC LABCORP HOLDINGS INC. LH · Entity 1277 Exercise / conversionRestricted Stock Unit · Derivative 893 $0.00 $0.00
Disclosure

SEC source: 0001127602-25-003711 · form4.xml · derivative · entry 3

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,787

Underlying: Common Stock · 893 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 6, 2025.

F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 6, 2025.

F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

Read SEC document
February 06, 2025 Filed Feb 10, 2025 14:00 UTC LABCORP HOLDINGS INC. LH · Entity 1277 Tax withholdingCommon Stock 336 $247.74 $83,240.64
Disclosure

SEC source: 0001127602-25-003711 · form4.xml · nonDerivative · entry 2

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 557

F2 · kind: Stock withholding to satisfy tax withholding obligations.

Read SEC document
February 06, 2025 Filed Feb 10, 2025 14:00 UTC LABCORP HOLDINGS INC. LH · Entity 1277 Exercise / conversionCommon Stock 893 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-25-003711 · form4.xml · nonDerivative · entry 1

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 893

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

Read SEC document
December 02, 2024 Filed Dec 4, 2024 15:05 UTC LABCORP HOLDINGS INC. LH · Entity 1277 GrantRestricted Stock Unit · Derivative 2,680 $0.00 $0.00
Disclosure

SEC source: 0001127602-24-028581 · form4.xml · derivative · entry 2

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,680

Underlying: Common Stock · 2,680 shares

Expires not disclosed

F3 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

F4 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025.

F4 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025.

Read SEC document
December 02, 2024 Filed Dec 4, 2024 15:05 UTC LABCORP HOLDINGS INC. LH · Entity 1277 GrantNon-qualified Stock Options · Derivative 8,100 $0.00 Strike: $240.63 $0.00
Disclosure

SEC source: 0001127602-24-028581 · form4.xml · derivative · entry 1

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,100

Underlying: Common Stock · 8,100 shares

Expires 2034-12-01

F1 · security: Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. Amended and Restated 2016 Omnibus Incentive Plan.

F2 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column.

Read SEC document
July 01, 2024 Filed Jul 3, 2024 17:05 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 472 $143.90 $67,918.68
Disclosure

SEC source: 0001651308-24-000080 · wk-form4_1720040726.xml · nonDerivative · entry 2

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 30, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.8513 to $144.06, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
June 24, 2024 Filed Jun 26, 2024 17:26 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 899 $155.66 $139,938.34
Disclosure

SEC source: 0001651308-24-000079 · wk-form4_1719437152.xml · nonDerivative · entry 2

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

Read SEC document
June 17, 2024 Filed Jun 20, 2024 17:26 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 314 $159.74 $50,158.61
Disclosure

SEC source: 0001651308-24-000074 · wk-form4_1718918780.xml · nonDerivative · entry 5

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 15, 2023, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.12 to $159.89, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
June 17, 2024 Filed Jun 20, 2024 17:26 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 253 $159.00 $40,226.52
Disclosure

SEC source: 0001651308-24-000074 · wk-form4_1718918780.xml · nonDerivative · entry 4

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 314

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 16, 2021, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.885 to $159.2191, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
June 17, 2024 Filed Jun 20, 2024 17:26 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 195 $158.58 $30,923.94
Disclosure

SEC source: 0001651308-24-000074 · wk-form4_1718918780.xml · nonDerivative · entry 3

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 567

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 15, 2023, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.40 to $160.33, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
June 17, 2024 Filed Jun 20, 2024 17:26 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 154 $158.24 $24,368.47
Disclosure

SEC source: 0001651308-24-000074 · wk-form4_1718918780.xml · nonDerivative · entry 2

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 762

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 15, 2023, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.10 to $159.05, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
June 05, 2024 Filed Jun 7, 2024 16:54 UTC BeOne Medicines Ltd. BGNE · Entity 2168 GrantShare Option (Right to Buy) · Derivative 256,659 $0.00 Strike: $12.23 $0.00
Disclosure

SEC source: 0001651308-24-000056 · wk-form4_1717793661.xml · derivative · entry 2

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 256,659

Underlying: Ordinary Shares · 256,659 shares

Expires 2034-06-04

F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.

F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.

F3 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Read SEC document
June 05, 2024 Filed Jun 7, 2024 16:54 UTC BeOne Medicines Ltd. BGNE · Entity 2168 GrantOrdinary Shares 136,240 $0.00 $0.00
Disclosure

SEC source: 0001651308-24-000056 · wk-form4_1717793661.xml · nonDerivative · entry 1

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 456,326

F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 5, 2024, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Read SEC document
February 29, 2024 Filed Mar 4, 2024 17:22 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 397 $167.08 $66,330.76
Disclosure

SEC source: 0001651308-24-000016 · wk-form4_1709590911.xml · nonDerivative · entry 2

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of February 28, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

Read SEC document
July 03, 2023 Filed Jul 6, 2023 17:02 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 472 $179.55 $84,747.36
Disclosure

SEC source: 0001651308-23-000104 · wf-form4_168867731225214.xml · nonDerivative · entry 2

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 30, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $179.5185 to $179.665, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
June 23, 2023 Filed Jun 27, 2023 17:22 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 840 $182.85 $153,594.00
Disclosure

SEC source: 0001651308-23-000102 · wf-form4_168790094090281.xml · nonDerivative · entry 2

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

Read SEC document
June 20, 2023 Filed Jun 20, 2023 18:51 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 190 $192.54 $36,583.00
Disclosure

SEC source: 0001651308-23-000091 · wf-form4_168730145579147.xml · nonDerivative · entry 2

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F2 · security: Each American Depositary Share represents 13 Ordinary Shares.

F3 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 16, 2021, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $192.50 to $192.58, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
June 15, 2023 Filed Jun 20, 2023 18:51 UTC BeOne Medicines Ltd. BGNE · Entity 2168 GrantShare Option (Right to Buy) · Derivative 409,058 $0.00 Strike: $16.41 $0.00
Disclosure

SEC source: 0001651308-23-000091 · wf-form4_168730145579147.xml · derivative · entry 3

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 409,058

Underlying: Ordinary Shares · 409,058 shares

Expires 2033-06-14

F5 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.

F5 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.

F6 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

Read SEC document
June 15, 2023 Filed Jun 20, 2023 18:51 UTC BeOne Medicines Ltd. BGNE · Entity 2168 GrantOrdinary Shares 107,770 $0.00 $0.00
Disclosure

SEC source: 0001651308-23-000091 · wf-form4_168730145579147.xml · nonDerivative · entry 1

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 342,303

F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 15, 2023, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

Read SEC document
March 01, 2023 Filed Mar 3, 2023 17:00 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 343 $240.21 $82,391.89
Disclosure

SEC source: 0001651308-23-000037 · wf-form4_167788080268388.xml · nonDerivative · entry 2

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of February 28, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $240.195 to $240.245, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
July 01, 2022 Filed Jul 5, 2022 17:29 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 295 $158.50 $46,757.50
Disclosure

SEC source: 0001651308-22-000119 · wf-form4_165705652132138.xml · nonDerivative · entry 2

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 30, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Read SEC document
July 01, 2022 Filed Jul 18, 2022 17:22 UTC Amendment BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 317 $158.50 $50,244.50
Disclosure

SEC source: 0001651308-22-000125 · wf-form4a_165817931742680.xml · nonDerivative · entry 2

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · security: Each American Depositary Share represents 13 Ordinary Shares.

F3 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 30, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

F1 · shares: The original Form 4, filed on July 5, 2022, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported a sale that occurred on July 1, 2022 as a total of 295 American Depositary Shares ("ADSs") sold when in fact 317 ADSs were sold. As a result of this administrative error, the number of Ordinary Shares beneficially owned by the reporting person following the corrected transaction reflects a reduction in the number of Ordinary Shares reported as beneficially owned by the reporting person by 286 Ordinary Shares.

Read SEC document
June 22, 2022 Filed Jun 24, 2022 17:40 UTC BeOne Medicines Ltd. BGNE · Entity 2168 GrantShare Option (Right to Buy) · Derivative 589,888 $0.00 Strike: $11.98 $0.00
Disclosure

SEC source: 0001651308-22-000112 · wf-form4_165610678473488.xml · derivative · entry 2

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 589,888

Underlying: Ordinary Shares · 589,888 shares

Expires 2032-06-21

F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares.

F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares.

F3 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of June 22, 2022 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

Read SEC document
June 22, 2022 Filed Jun 24, 2022 17:40 UTC BeOne Medicines Ltd. BGNE · Entity 2168 GrantOrdinary Shares 104,377 $0.00 $0.00
Disclosure

SEC source: 0001651308-22-000112 · wf-form4_165610678473488.xml · nonDerivative · entry 1

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 245,583

F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

Read SEC document
June 17, 2022 Filed Jun 21, 2022 17:09 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 161 $136.64 $21,998.93
Disclosure

SEC source: 0001651308-22-000084 · wf-form4_165584573671205.xml · nonDerivative · entry 2

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 16, 2021, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Read SEC document
February 28, 2022 Filed Mar 2, 2022 17:12 UTC BeOne Medicines Ltd. BGNE · Entity 2168 GrantOrdinary Shares 61,750 $0.00 $0.00
Disclosure

SEC source: 0001651308-22-000035 · wf-form4_164625910284672.xml · nonDerivative · entry 1

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 143,299

F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of February 28, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

F2 · balance_after: Includes 1,677 ordinary shares acquired pursuant to the Company's Second Amended and Restated 2018 Employee Share Purchase Plan.

Read SEC document
July 01, 2021 Filed Jul 1, 2021 16:58 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 308 $349.06 $107,511.68
Disclosure

SEC source: 0001651308-21-000147 · wf-form4_162517305797222.xml · nonDerivative · entry 2

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 30, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $348.9264 to $349.35, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.